Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing...
May 07, 2025 02:30 ET | Source: Monopar Therapeutics Inc.

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with...
April 29, 2025 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with...
March 31, 2025 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with...
December 20, 2024 09:00 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative...
December 05, 2024 16:21 ET | Source: Monopar Therapeutics Inc.

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...
December 03, 2024 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...
November 08, 2024 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid...
October 30, 2024 13:42 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...
October 28, 2024 21:15 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...

Next Page keyboard_arrow_right